Aikium

Aikium is a Berkeley-based biotechnology company specializing in the discovery and development of next-generation protein therapeutics for neuro-inflammation and oncology. The company utilizes its proprietary AI platform, Yotta-ML², and a trillion-scale mRNA display system called Yotta Display to engineer "SeqR" proteins—non-antibody scaffolds designed to bind to intrinsically disordered regions and "undruggable" targets like GPCRs. By navigating a massive combinatorial space of protein sequences, Aikium aims to create precise, programmable binders with universal target coverage. The company's pipeline includes candidates targeting metabolic receptors, checkpoint inhibitors, and cancer-associated antigens. Aikium operates out of the Bakar Bioenginuity Hub and has established partnerships with major cancer research institutions and pharmaceutical companies.